摘要
左旋多巴不仅可以改善帕金森病(PD)患者的运动症状、提高日常生活能力、增加独立性,还可延长患者的寿命、降低病死率。自左旋多巴应用于临床40年来,是治疗PD最有效的药。由于长期使用左旋多巴会出现运动并发症,加速PD病理进展而具神经毒性,长期使用会失去疗效。Olanow等(2001)公布的PD治疗指南更倾向于以受体激动剂启动PD治疗。然而随着研究的深入,发现运动并发症与左旋多巴剂量、疾病严重性、年龄等多种因素相关。受体激动剂尽管短期可以延迟运动并发症的发生,但并无此长期优势。临床上没有证据表明左旋多巴加速病理进程及有神经毒性。因此,本文就以上问题进行综述,探讨小剂量左旋多巴启动治疗早期PD的作用。
Levodopa can not only improve the motor symptoms of Parkinson＇ s disease （PD） patients, improving their daily lives and increasing the independence, but also reduce mortality and prolong life time. Levodopa has been considered as the gold standard for 40 years in the treatment of PD. While being worried about the motor complications, accelerating PD pathology progress and losing the efficacy, the early guideline of levodopa was more inclined to activate agonists as initial treatment. However, it was found that motor complications are associated with many factors. Agonists can delay the occurrence of motor complications in short-term, and have no use in long-term. There is no evidence to suggest that levodopa has neurotoxicity and can accelerate the pathologic process. The advantages of low dose of levodopa in early initial treatment for PD were reviewed.
出处
《中国临床神经科学》
2013年第2期178-181,共4页
Chinese Journal of Clinical Neurosciences
关键词
帕金森病
启动治疗
剂量
左旋多巴
Parkinson＇s disease
initialtreatment
dosage
levodopa
